Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Anti-inflammatory agent 17 an orally active anti-inflammatory agent, demonstrates potent efficacy in inhibiting the release of IL-6 and TNF-α without causing cytotoxicity in in vitro experiments. Furthermore, in vivo studies confirm its anti-inflammatory activity. Given its attributes, Compound 17 holds promise for investigating Acute lung injury (ALI) [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | Anti-inflammatory agent 17 an orally active anti-inflammatory agent, demonstrates potent efficacy in inhibiting the release of IL-6 and TNF-α without causing cytotoxicity in in vitro experiments. Furthermore, in vivo studies confirm its anti-inflammatory activity. Given its attributes, Compound 17 holds promise for investigating Acute lung injury (ALI) [1]. |
体外活性 | Anti-inflammatory agent 17 (compound 5b) (10 μM; 24 h) displays no toxicity in J774a.1 cells [1]. Anti-inflammatory agent 17 (1.25, 2.5, 5, 10 μM; 2 h) inhibits the production of IL-6 (IC 50 =8.254 μM) and TNF-α (IC 50 =2.576 μM) in J774a.1 cells in a dose-dependent manner [1]. Cell Viability Assay [1] Cell Line: J774a.1 cells Concentration: 10 μM Incubation Time: 24 h Result: Displayed no toxicity in J774a.1 cells. Immunofluorescence [1] Cell Line: J774A.1 cells Concentration: 1.25, 2.5, 5, 10 μM Incubation Time: 2 h Result: Inhibited the production of IL-6 (IC 50 =8.254 μM) and TNF-α (IC 50 =2.576 μM) in J774a.1 cells in a dose-dependent manner. |
体内活性 | Anti-inflammatory agent 17 (20 mg/kg; intragastric administration) exhibits protective effect on LPS (lipopolysaccharide)-induced ALI in mice [1]. Animal Model: C57/BL6 mice [1] Dosage: 20 mg/kg Administration: Intragastric administration Result: Exhibited protective effect on LPS-induced ALI in mice. |
分子量 | 357.4 |
分子式 | C20H23NO5 |
CAS No. | 2763226-84-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Anti-inflammatory agent 17 2763226-84-0 Inhibitor inhibitor inhibit